2022-12-13-世界卫生组织-ACT-Accelerator_Outcomes_Report,_2020-22_46页_7mb

ACT-Accelerator Outcomes Report, 2020-2022 Summary

Introduction

The report covers cumulative achievements since the start of the COVID-19 pandemic and outlines the outcomes of the four-pillar strategy for the 2021-2022 Strategic Plan. The transition period (October 2022–March 2023) focuses on integrating COVID-19 tools into routine healthcare.

Key Achievements by ACT-A Pillars

Vaccines Pillar

• Secured 2.62 billion vaccine doses through Advance Purchase Agreements and donations.
• 1.94 billion doses allocated and accepted across 146 countries.
• 1.77 billion doses delivered by the end of Q3 2022.
• Increased vaccination coverage: 75% of doses in LICs came from COVAX.

Diagnostics Pillar

• Secured 185.5 million tests for 182 countries.
• 34 diagnostic tools received WHO Emergency Use Listing (EUL).
• Conducted genomic sequencing in 77% of WHO member states (15 out of 190) by October 2022.
• Sustained price reductions: PCR tests from $20–$30 to <$10; Ag-RDTs reduced to $1–$2.

Therapeutics Pillar

• Secured US$25.2 million worth of COVID-19 medications.
• Procured 56,000 Nm³ of oxygen per day via market shaping and regional manufacturing.
• Prequalified 9 COVID-19 therapeutics: Including molnupiravir and nirmatrelvir/ritonavir.

Health Systems and Response Connector

• Awarded US$88.9 billion in funding through various mechanisms.
• Procured US$249 million in PPE for health workers.
• Developed capacity for 196 countries to use the WHO ECLP digital tool for planning.

Breakthrough Progress

Oxygen Access

• 50 oxygen plants repaired or installed.
• 19,300 oxygen concentrators delivered (8,000 by the Global Fund and 11,300 by UNICEF).

Test-and-Treat Strategy

• Supported 180,000 HCWs through training.
• Integrated testing and treatment into primary healthcare settings.

Market Shaping

• Unitaid brokered price negotiations with suppliers, reducing oxygen costs by 15% for bulk and 10–50% for cylinders.

Looking Ahead

• AMC funding targets: Include equitable access to diagnostics and treatments.
• Inclusive financing framework: Champions equity and transparency to accelerate global health architecture for future pandemics.

| Pillar         | Metrics                      | Result                          |
|----------------|-----------------------------|---------------------------------|
| Vaccines       | Doses procured/allocated    | 2.62B secured, 1.94B allocated |
| Diagnostics    | EUL-approved tools           | 34 tools                         |
| Therapeutics   | Antiviral molnupiravir       | Prequalified                    |
| Health Systems | Oxygen procurement           | 56,000 Nm³ daily capacity       |